We work with your healthcare provider to deliver a range of personalised tests so you can choose the best treatment together.
More patient informationFind answers to some of your most frequently asked questions
New methods and reliable tests to help deliver personalised treatment
RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.
The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.
Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off.
Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.
ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.
Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs).
Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.
Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.
Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer.
Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.
Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood.
Find out more about our latest research, trials, and education days.
We are delighted to be one of the main sponsors at the 13th Day of Life Sciences on 9th June 2022. Register for the symposium ‘Competencies in Drug Discovery’ by 7th June, we look forward to seeing you there! Day of Life Sciences | ZHAW Life Sciences and Facility Management
Scientists have identified a mutated gene that causes breast cancer to become more aggressive and spread to other parts of the body in up to 30% of patients. The discovery provides exciting new avenues to develop new treatments for breast cancer, including more effective personalised approaches. Hormone therapy effectively treats around two-thirds of breast cancers, […]
German scientists have identified the proteins inside colon cancer cells that trick the immune system from seeing them as a threat. But, in lab tests, once researchers blocked the signals from the cells, the immune systems began to attack them. The insight could help scientists develop new and highly targeted immunotherapies for one of the […]
Scientists have discovered new and more effective ways of growing breast cancer tumours that could accelerate research and the development of new treatments. Instead of transplanting human tumours into mice, they’ve developed a bank of “human patient-derived xenografts (PDXs)” that can be used to screen drugs. Used alongside personalised genetic tests could improve cancer treatment […]
Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies. Supportive oligonucleotide therapy is an advanced, […]
